Vigil Neuroscience Presents VGL101 Complete Phase 1 Data And Phase 2 Ignite Trial Design At The 2023 American Neurological Association Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Vigil Neuroscience has presented complete Phase 1 data and Phase 2 IGNITE trial design at the 2023 American Neurological Association Annual Meeting. The data showed that VGL101 has a favorable safety and tolerability profile and proof-of-target engagement in SAD/MAD cohorts up to 60 mg/kg. The company is on track to report 6-month interim data from the IGNITE trial in Q4 2023.
September 11, 2023 | 4:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vigil Neuroscience's positive Phase 1 data for VGL101 and the upcoming interim data from the IGNITE trial could potentially boost investor confidence and positively impact the company's stock in the short term.
Positive clinical trial results often lead to increased investor confidence, which can drive up a company's stock price. The announcement of the upcoming interim data from the IGNITE trial also creates anticipation, which could further boost the stock.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100